Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$5.18M+611.13%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Erez Raphael
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 163
- Beta
- 1.12
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -6.79
Financials
Revenue
$5.18M+611.1%Net Income
$-7.92MEBITDA
$-5.96MFree Cash Flow
$-5.53MEPS (diluted)
$-0.85Shares Outstanding (diluted)
9.34M+3175.5%Operating Expenses
$9.67MCash & Debt
$14.25MReturn of Capital
$0.00Revenue by Segment (annual)
$14.93MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $22.36M | $-41.71M | $-0.81 |
| 2024 | $27.04M | $-42.75M | $-0.74 |
| 2023 | $20.35M | $-59.43M | $-1.93 |
| 2022 | $27.66M | $-62.19M | $-2.63 |
| 2021 | $20.51M | $-76.76M | $-4.63 |
| 2020 | $7.58M | $-29.45M | $-5.55 |
| 2019 | $7.56M | $-17.74M | $-7.84 |
| 2018 | $7.39M | $-17.80M | $-15.21 |
| 2017 | $5.17M | $-15.74M | $-32.70 |
| 2016 | $2.80M | $-10.89M | $-41.85 |
| 2015 | $823.0K | $-7.14M | $-75.27 |
| 2014 | $51.0K | $-12.88M | $-534.14 |
| 2013 | $0.00 | $-13.93M | $-1369.35 |
| 2012 | $0.00 | $-5.69M | $-512.72 |
Valuation
DRIOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-78.95%Social Signal Score
Mentions (4)
- Newsprnewswire.com·19d ago·Negative
…lth plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida NEW YORK, Sept. 17, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced a new contract with a leading health plan in New Jersey, one of the largest in the state representing approximately 1.5 million covered lives.
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
DarioHealth Q2 Earnings Call Highlights DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.
View source ↗ - Newszacks.com·56d ago·Negative
DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.
View source ↗ - Newsprnewswire.com·56d ago·Neutral
DarioHealth Reports Second Quarter 2026 Financial Results Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter Operating expenses decl
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.51 per share
Typical surprise +25.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.85 vs $-1.22beat
- Wed, May 13$-0.81 vs $-1.09beat
- Thu, Mar 19$-0.80 vs $-2.44beat
- Thu, Nov 13$-1.85 vs $-3.97beat
- Tue, Aug 12$-2.40 vs $-2.20miss
- Wed, May 14$-1.20 vs $-1.40beat
Estimates and results for DRIO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DRIO officers and directors.
- Bought
- $193k
- Sold
- $895k
24 trades
10 trades
- Matheis Dennisbought
- Nelson Steven Charlesbought
- Stern Adam Kbought
- Nelson Steven Charlesbought
- Nelson Steven Charlesbought
- Nelson Steven Charlesbought
- Nelson Steven Charlesbought
- Nelson Steven Charlesbought
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DRIO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.